Shenzhen Salubris Pharmaceuticals Co Ltd

Price Chart

Risk-Adjusted Performance

Shenzhen Salubris Pharmaceuticals Co Ltd (002294) Price Performance

Shenzhen Salubris Pharmaceuticals Co Ltd (002294) trades on SHE in CNY. The company is classified in the Healthcare sector under the Drug Manufacturers - Specialty & Generic industry. The stock currently trades at CNY56.03, down 3.56% from the previous close.

Over the past year, 002294 has traded between a low of CNY29.73 and a high of CNY62.46. The stock has gained 88.4% over this period. It is currently 10.3% below its 52-week high.

Shenzhen Salubris Pharmaceuticals Co Ltd has a market capitalization of $64.77B and a dividend yield of 86.00%.

About Shenzhen Salubris Pharmaceuticals Co Ltd

Shenzhen Salubris Pharmaceuticals Co., Ltd. engages in the research, development, production, and sale of medicines and medical devices in China. The company offers drugs for various therapeutic fields, such as thrombosis, hypertension and related diseases, osteoporosis, and infections, as well as anti-osteolysis, antiallergic, antiepileptic, and antidepressant medicines. It also develops Sacubitril Allisartan Calcium, Allisartan Isoproxil Amlodipine Besylate Tablets, and Allisartan IsoproxilIndapamide Sustained-release Tablets, which are in phase III clinical trial for treatment of hypertension; Enarodustat, a drug for renal anemia; SAL056, SAL001, SAL023 medicine used for treating osteoporosis; and Fotagliptin, and SAL015 for diabetes which are under phase III clinical trial. Further, it develops Sacubitril Allisartan Calcium and SAL007 medicine for chronic heart failure; SAL003 to treat hypercholesterolemia; and SAL0114 for depressant indications that is in phase I clinical trial. Additionally, the company's preclinical products are SAL023 for osteoporosis; SAL0112 to treat diabetes; and SAL008 for the treatment of tumors. Furthermore, it develops medical devices. The company was incorporated in 1998 and is headquartered in Shenzhen, China. Shenzhen Salubris Pharmaceuticals Co., Ltd. is a subsidiary of Salubris Pharmaceuticals Co., Ltd.